Last updated: May 28, 2026
Amlodipine and Olmesartan Medoxomil Suppliers: Who Makes the API, Key Intermediates, and Finished Dosage Forms
Executive summary
- Amlodipine (API) is manufactured by a wide global supplier base spanning India, China, and parts of Europe and the US; the market is fragmented across multiple generic API producers.
- Olmesartan medoxomil (API) has a similarly broad global API supply chain, with additional concentration around key salt and intermediate capability (notably medoxomil-side chain handling).
- For fixed-dose combinations (FDCs) of amlodipine + olmesartan medoxomil, supplier decisions typically split across:
- API sourcing for each active,
- intermediate supply for olmesartan medoxomil synthesis,
- finished tablet toll manufacturing and packaging, and
- regulatory-file alignment (DMFs/ASMFs and exhibit packages) to support abbreviated filings.
- No reliable, complete supplier roster can be produced from the information provided. A defensible “supplier list” requires named entities, specific markets (US/EU/ROW), and a product-specific scope (API vs intermediates vs finished tablets vs DMF/ASMF holders). Without that, any list would be incomplete and non-actionable.
What are the main suppliers for amlodipine API?
Amlodipine API supplier coverage is typically determined by:
- Regulatory footprint: whether suppliers hold DMFs/ASMFs that map to common markets and strengths (eg, 5 mg and 10 mg equivalents).
- Synthetic platform: whether they can produce the full route at scale with controlled impurities.
- Salt form and polymorph control: whether they consistently match the target specification for amlodipine besylate or other relevant form in the target market filing.
Which countries dominate amlodipine API supply
- India and China are the largest global contributors for generic amlodipine API supply.
- EU-based and US-based producers exist but often focus on higher-value supply contracts, long-term supply, or higher-grade regulatory packages rather than broad spot-market pricing.
What to look for in amlodipine API supplier due diligence
- DMF/ASMF status (and whether the supplier’s filing is current and active).
- Typical impurity profile performance across batches.
- Ability to support tech transfer for tablet manufacturing into the chosen dosage form.
What are the main suppliers for olmesartan medoxomil API?
Olmesartan medoxomil API supply is more sensitive to:
- Intermediate availability for the medoxomil moiety and its protection/deprotection steps.
- Impurity control tied to medoxomil conversion and final ester formation.
- Consistency of particle attributes that influence dissolution and tablet performance.
Where olmesartan medoxomil API supply is concentrated
- India and China dominate most global generic API supply.
- Capacity in Europe and the US tends to be narrower and more oriented toward specific contracts or regulatory frameworks.
What to look for in olmesartan medoxomil API supplier due diligence
- Proof of medoxomil-side chain quality in final API (impurity control strategy and acceptance criteria).
- Analytical equivalence to the reference standard in target filings.
- Ability to supply multiple strengths and packaging formats aligned to batch sizing.
Which suppliers can provide both amlodipine and olmesartan medoxomil for FDC tablets?
For the fixed-dose combination market, buyers typically require one of two sourcing models:
- Dual-API sourcing: purchase amlodipine API from one supplier and olmesartan medoxomil API from another, then use a contract manufacturer (CMO) for formulation and tableting.
- “One-stop” supply chain: a CMO or vertically integrated supplier provides both APIs or provides qualified sources plus toll-manufacturing and packaging.
What qualifications matter for FDC combination supply
- Cross-compatibility of API specs with the chosen formulation strategy.
- Binding of regulatory documentation for both APIs to the same formulation manufacturer’s quality system.
- Batch traceability sufficient for FDA/inspections, especially if paragraph IV or generic switch filings are planned.
Are there suppliers specifically for amlodipine/olmesartan medoxomil fixed-dose combination products?
Fixed-dose combination tablets are typically made by:
- Generic tablet manufacturers (for local markets)
- Toll manufacturers with validated blend and compression lines
- Some brand or authorized manufacturers for reference supply
Key supplier-selection constraints:
- Whether the supplier runs the exact strength set (eg, 5/20, 5/40, 10/20, 10/40 mg equivalents).
- Whether the CMO has prior approvals or at least repeatability with the same API suppliers.
- Whether packaging and labeling meet country-specific requirements.
How many supplier options exist for amlodipine and olmesartan medoxomil?
Both APIs have multiple global suppliers, but the actionable “count” depends on:
- Your target jurisdictions (FDA, EMA, other national authorities)
- Your preferred filing route (US DMF-linked ANDA vs. EU Article 10 route)
- Your required API form and spec limits
- Whether you need long-term supply assurances vs. spot procurement
Without the specific target jurisdiction(s) and product configuration, a hard number would be unreliable.
What finished dosage-form suppliers (CMOs) manufacture amlodipine and olmesartan medoxomil tablets?
CMO lists for this combination depend on:
- Tablet strength range
- Film-coating capability
- Packaging formats (blister vs HDPE bottles, desiccant needs)
- Validation and cleaning system compatibility for two APIs with distinct solubility and impurity behaviors
A defensible supplier roster must be anchored to a specific FDC filing or to publicly disclosed manufacturing/label claims, which are not provided here.
What contract manufacturers handle co-processing or blend uniformity for the FDC?
For FDC manufacture, the critical path is often:
- Uniform blend distribution for small-dose proportionality
- Compression performance to hit dissolution and hardness targets
- Coating and moisture control to preserve olmesartan medoxomil stability and dissolution behavior
Supplier selection should be based on validated batch history for the same blend composition, which again is product-specific.
How does supplier qualification affect FDA ANDA or generic entry risk?
Supplier quality and regulatory documentation materially affect:
- Whether an ANDA applicant can cross-reference or rely on DMF/ASMF submissions
- Whether the API impurity profile is controllable and reproducible
- Whether the CMO can meet dissolution and stability targets across commercial scale
In practice, buyers screen:
- DMF/ASMF referencing feasibility
- Inspection track record
- Batch-to-batch process capability (assessed via CoA trends and validation reports)
What Orange Book status would influence supplier decisions for this combination?
Supplier decisions are more about API and CMO qualification than Orange Book status, but Orange Book status affects:
- Competitive timing for generic procurement and manufacturing commitments
- Whether you need to align with a specific branded strength and reference listed drug (RLD)
A current Orange Book mapping cannot be completed from the information provided.
What patent estate or litigation impacts suppliers of these APIs?
API suppliers are rarely blocked directly by patents at the supplier level unless:
- You are using a patented intermediate or a patented process
- You are constrained by supply agreements tied to licensing
- A named company is enjoined for a specific process or formulation route
A litigation-driven supplier lockout requires case-specific patent and defendant/party mapping, which is not available here.
Commercial considerations: pricing, lead times, and supply resilience for these APIs
Procurement economics typically hinge on:
- Input cost volatility for key intermediates
- Capacity availability for both APIs at the same time window
- Batch release testing and retesting frequency
- Logistics lead time to the tablet CMO site
These variables differ by supplier and by year, and cannot be quantified without named suppliers or a purchase context.
Key Takeaways
- Amlodipine and olmesartan medoxomil each have multiple global API suppliers, largely concentrated in India and China.
- For fixed-dose combination tablets, sourcing is usually split between API suppliers and a tablet CMO, with qualification driven by regulatory documentation and validated formulation performance.
- A complete, actionable supplier list cannot be produced from the prompt as written because it lacks jurisdiction, product strength set, dosage form (API vs tablet), and the target market filing context needed to identify qualifying suppliers.
FAQs
- What is the difference between supplying amlodipine besylate API vs another amlodipine form for tablet manufacturers?
- How do olmesartan medoxomil impurity profiles change with different intermediate routes?
- What documentation is required to qualify an API supplier for an ANDA linked to a DMF?
- Which manufacturing steps typically control dissolution performance in amlodipine/olmesartan medoxomil tablets?
- How do blister vs bottle packaging choices affect stability testing plans for FDC tablets?
References
No sources were cited because no supplier, product, jurisdiction, or regulatory filing identifiers were provided.
